Adjuvant Immunotherapy Benefit in Resected Kidney Cancer Adjuvant Immunotherapy Benefit in Resected Kidney Cancer
After surgery, progression-free survival was significantly longer for patients with high-risk renal carcinoma who received immunotherapy with pembrolizumab than for those who received placebo.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Hematology | Immunotherapy | Kidney Cancer | Urology & Nephrology